Royal Bank of Canada Boosts Holdings in Grifols, S.A. $GRFS

Royal Bank of Canada raised its position in Grifols, S.A. (NASDAQ:GRFS) by 15.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 785,703 shares of the biotechnology company’s stock after acquiring an additional 104,850 shares during the period. Royal Bank of Canada owned approximately 0.12% of Grifols worth $6,301,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Grifols by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 1,212 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Grifols by 50.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,961 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 2,998 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Grifols by 127.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 4,604 shares in the last quarter. Allworth Financial LP grew its stake in Grifols by 15.7% during the 4th quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock worth $75,000 after buying an additional 1,096 shares during the last quarter. Finally, Ameriprise Financial Inc. purchased a new position in Grifols during the 2nd quarter worth $95,000.

Grifols Stock Performance

Shares of GRFS opened at $7.99 on Wednesday. The stock has a 50-day moving average of $7.52 and a two-hundred day moving average of $8.12. Grifols, S.A. has a one year low of $6.96 and a one year high of $10.84. The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.81 and a current ratio of 2.37. The stock has a market cap of $5.44 billion, a P/E ratio of 42.05, a P/E/G ratio of 0.29 and a beta of 0.67.

Grifols Announces Dividend

The company also recently announced a special dividend, which was paid on Thursday, July 9th. Investors of record on Thursday, July 2nd were issued a dividend of $0.0945 per share. The ex-dividend date of this dividend was Thursday, July 2nd. Grifols’s payout ratio is 121.05%.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Zacks Research upgraded Grifols from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Wall Street Zen lowered Grifols from a “buy” rating to a “hold” rating in a research note on Monday, May 18th. Finally, Weiss Ratings downgraded shares of Grifols from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, July 31st. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Grifols presently has an average rating of “Reduce” and an average price target of $10.00.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.